Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cirius Therapeutics is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of liver and metabolic diseases. Cirius is developing MSDC-0602K, a novel, once-daily, oral small molecule for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K is designed to selectively modulate the mitochondrial pyruvate carrier (MPC), which mediates at the cellular...
Cirius Therapeutics is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of liver and metabolic diseases. Cirius is developing MSDC-0602K, a novel, once-daily, oral small molecule for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K is designed to selectively modulate the mitochondrial pyruvate carrier (MPC), which mediates at the cellular level the effects of overnutrition, a major cause of NASH and other metabolic disorders.

List your booth number for exhibitions, ask us